Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mutiple myeloma

- PMLiVE

Market researchers must become internal consultants

Bayer's Dr Thomas Hein gives his first interview as president of the European Pharmaceutical Market Research Association

- PMLiVE

Pfizer set for negative NICE decision on Inlyta

Institute's draft guidance doesn't recommend drug for advanced kidney cancer

- PMLiVE

BMS cuts Orencia price to win NICE over

Draft guidance now backs drug for earlier stage of rheumatoid arthritis treatment

- PMLiVE

Swedish approval for Bayer’s long-term contraceptive Jaydess

Country is reference member state for approval under the decentralised EU procedure

- PMLiVE

NICE backs Servier’s heart failure drug Procoralan

But recommendation includes a number of restrictions that limit NHS use of the drug

- PMLiVE

Bayer’s eye drug Eylea approved in Europe

Will compete with Novartis' Lucentis in wet AMD

- PMLiVE

Reckitt beats Bayer to acquire nutrition company Schiff

Provides springboard to US consumer health market

- PMLiVE

Bayer’s Xarelto cleared in Europe for pulmonary embolism and DVT prevention

Gives further edge over Boehringer’s anticoagulant Pradaxa

- PMLiVE

Reckitt trumps Bayer with $1.4bn bid for Schiff Nutrition

Could spark bidding war for the consumer health company

- PMLiVE

New hope for castration-resistant prostate cancer

An unprecedented number of therapies have reached late-stage clinical trials or been approved over recent years targeting this disease with an unmet medical need

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

NICE to reverse approval for Novartis’ asthma drug Xolair

Draft guidance doesn't recommend omalizumab for severe asthma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links